

Supplemental Table S1. Cx43 phosphorylation in NP-UAEC with VEGF-165, VEGF-E or PIGF and without or with VEGFR kinase inhibitor (VEGFRi).¹

	Control		VEGF-165		VEGF E		PIGF	
	-VEGFRi	+VEGFRi	-VEGFRi	+VEGFRi	-VEGFRi	+VEGFRi	-VEGFRi	+VEGFRi
Ser-279								
46 kDa	1.00	1.15±0.06+	1.26±0.08*	1.00±0.06+#	1.26±0.10*	0.97±0.06+#	0.95±0.11 [§]	1.00±0.09
Tyr-265								
82-78 kDa	1.00	0.98±0.09	1.13±0.02*	0.91±0.08+	0.97±0.10	0.90±0.08	0.91±0.09	0.76±0.06*
82 kDa	1.00	0.96±0.07	1.07±0.08	0.91±0.10	0.96±0.11	0.96±0.14	0.92±0.12	0.74±0.07*
80 kDa	1.00	0.93±0.08	1.11±0.07	0.88±0.09+	0.98±0.13	0.90±0.12	0.92±0.11	0.74±0.06*
78 kDa	1.00	1.02±0.07	1.12±0.10	0.96±0.07+	0.95±0.10	0.95±0.11	0.94±0.09	0.79±0.05*
46 kDa	1.00	0.84±0.08	0.91±0.06	0.88±0.07	0.95±1.10	0.86±0.10	0.85±0.13	0.79±0.05
42 kDa	1.00	0.90±0.08	0.96±0.09	0.93±0.09	0.98±0.14	0.90±0.15	0.82±0.17	0.81±0.11
Ser-368								
46 kDa	1.00	1.00±0.06	1.04±0.08	0.82±0.07*+	0.95±0.05	0.90±0.04*	0.96±0.03	0.84±0.03*+
42 kDa ²	1.00	0.88±0.04+	1.00±0.07	0.77±0.09*	0.91±0.06	0.83±0.10	0.90±0.06	0.67±0.06*+
Ser-262								
All bands	1.00	1.03±0.07	1.03±0.08	0.98±0.06	1.01±0.05	0.92±0.05	1.01±0.04	0.99±0.04
42-46 kDa	1.00	1.03±0.12	1.02±0.09	0.95±0.09	0.97±0.08	0.92±0.08	1.02±0.06	0.97±0.12
46 kDa	1.00	1.06±0.11	1.05±0.06	1.01±0.08	0.99±0.07	1.00±0.09	1.05±0.05	1.05±0.12
44 kDa	1.00	0.99±0.15	0.89±0.11	0.89±0.08	0.95±0.09	0.86±0.08	0.89±0.07	0.92±0.16
42 kDa	1.00	1.09±0.09	0.99±0.13	0.95±0.08	0.97±0.09	0.86±0.06*	0.97±0.13	0.88±0.12
36 kDa	1.00	1.05±0.06	1.02±0.08	0.98±0.04	1.00±0.06	0.84±0.06*	0.99±0.08	0.87±0.10
32 kDa	1.00	0.99±0.06	1.44±0.10*	1.12±0.13+	1.33±0.12*	1.20±0.10*	1.05±0.13 [§]	1.05±0.12
28 kDa	1.00	1.08±0.06	1.03±0.08	1.12±0.05	1.07±0.09	0.98±0.06	0.97±0.19	1.02±0.05
Total Cx43								
All bands	1.00	1.13±0.03+	1.14±0.04*	1.03±0.03+	1.11±0.03*	1.11±0.04*	1.17±0.05*#	1.02±0.10
46-47 kDa	1.00	1.13±0.05+	1.17±0.03*	1.11±0.05*	1.18±0.05*	1.16±0.07*	1.22±0.06*#	1.09±0.12
42-43 kDa	1.00	1.13±0.03+	1.11±0.06	0.98±0.03	1.08±0.03*	1.06±0.04	1.16±0.08	1.01±0.11
CT1³								
42-43 kDa	1.00	1.06±0.05	1.01±0.02	1.04±0.05	1.05±0.03	1.00±0.04	1.06±0.03	0.99±0.04

¹Values shown are Means ± S.E.M. for 5–6 independent experiments (for the 28 kDa band of s262, n=3). Following frequently used nomenclature, 42 kDa=P0, 43 kDa=P1, 46 kDa=P2; 47 kDa=P3. Because some bands were difficult to measure separately due to their proximity, they were measured together.

²This band increases with alkaline phosphatase treatment.

³CT1 antibody recognizes Cx43 when Ser-365 is not phosphorylated.

* P<0.05 compared with control, + P<0.05 compared with same stimulated without inhibitor. # P<0.05 compared with P-UAEC, [§]P<0.05 compared with VEGF165.

Supplemental Table S2. Cx43 phosphorylation in P-UAEC with VEGF-165, VEGF-E or PIGF and without or with VEGFR kinase inhibitor (VEGFRi)¹

	Control		VEGF-165		VEGF E		PIGF	
	-VEGFRi	+VEGFRi	-VEGFRi	+VEGFRi	-VEGFRi	+VEGFRi	-VEGFRi	+VEGFRi
Ser-279								
46 kDa	1.00	0.96±0.10	1.41±0.07*	1.35±0.11*#	1.51±0.14*	1.50±0.14*#	1.06±0.08 [§]	0.97±0.17 [§]
Tyr-265								
82-78 kDa	1.00	1.05±0.07	1.26±0.12*	1.13±0.12+	1.26±0.11*	1.10±0.11+	1.18±0.12	1.11±0.11
82 kDa	1.00	1.05±0.15	1.26±0.19	1.24±0.21	1.26±0.18	1.13±0.20	1.13±0.18	1.18±0.18
80 kDa	1.00	0.94±0.09	1.19±0.14	1.08±0.15	1.18±0.13	1.00±0.12+	1.02±0.10	0.99±0.09
78 kDa	1.00	0.95±0.09	1.05±0.10	1.06±0.16	1.17±0.14	1.00±0.11+	1.04±0.10	0.99±0.10
46 kDa	1.00	0.80±0.07+	0.93±0.07	0.85±0.07	0.95±0.10	0.79±0.08	0.89±0.08	0.90±0.08
42 kDa	1.00	0.78±0.10+	0.92±0.09	0.76±0.10	0.88±0.11	0.71±0.08	0.77±0.13	0.72±0.09
Ser-368								
46 kDa	1.00	0.94±0.06	0.95±0.07	0.92±0.06	0.94±0.06	0.96±0.11	0.98±0.08	0.92±0.06
42 kDa ²	1.00±	1.08±0.10	1.23±0.15	1.00±0.17	1.22±0.16	1.03±0.11	1.04±0.15	0.88±0.15
Ser-262								
All bands	1.00	1.04±0.07	1.06±0.07	1.06±0.06	1.14±0.11	1.13±0.11	1.04±0.06	1.09±0.10
42-46 kDa	1.00	1.04±0.09	1.07±0.07	1.06±0.06	1.06±0.10	1.06±0.11	1.06±0.05	1.10±0.10
46 kDa	1.00	1.00±0.07	1.06±0.05	1.09±0.03	1.05±0.07	1.07±0.06	1.11±0.03*	1.13±0.05*
44 kDa	1.00	1.01±0.10	1.09±0.11	1.07±0.09	1.02±0.12	0.98±0.18	1.05±0.11	1.08±0.16
42 kDa	1.00	1.07±0.14	1.05±0.12	1.09±0.10	1.10±0.15	1.07±0.20	1.04±0.11	1.16±0.18
36 kDa	1.00	1.00±0.07	1.00±0.06	0.99±0.05	1.04±0.10	1.07±0.10	0.96±0.07	0.98±0.07
32 kDa	1.00	0.99±0.12	1.40±0.08*	1.39±0.18*	1.66±0.23*	1.57±0.24*	1.27±0.12*	1.18±0.11
28 kDa	1.00	1.15±0.13	1.10±0.14	1.05±0.16	1.09±0.14	1.05±0.13	0.87±0.05	0.96±0.09
Total Cx43								
All bands	1.00	1.07±0.06	1.12±0.08	0.93±0.07	1.05±0.07	1.03±0.07	0.99±0.06#	1.00±0.09
46-47 kDa	1.00	1.04±0.03	1.14±0.06*	1.04±0.08	1.09±0.06	1.04±0.04	1.01±0.05#	0.99±0.09
42-43 kDa	1.00	1.12±0.11	1.11±0.12	0.88±0.08	1.03±0.09	1.01±0.09	1.00±0.10	1.01±0.09
CT1³								
42-43 kDa	1.00	1.01±0.06	1.08±0.06	1.08±0.08	1.02±0.04	0.97±0.07	1.08±0.07	1.00±0.08

¹Values shown are Means ± S.E.M for 5–6 independent experiments (for the 28 kDa band of Ser-262, n=3). Following frequently used nomenclature, 42 kDa=P0, 43 kDa=P1, 46 kDa=P2; 47 kDa=P3. Because some bands were difficult to measure separately due to their proximity, they were measured together.

²This band increases with alkaline phosphatase treatment.

³CT1 antibody recognizes Cx43 when Ser-365 is not phosphorylated.

* P<0.05 compared with control, + P<0.05 compared with same stimulated without inhibitor. # P<0.05 compared with NP-UAEC, § P<0.05 compared with VEGF 165.

Supplemental Table S3. Cx43 phosphorylation in NP-UAEC with PMA, ATP or VEGF-165 and without or with U0126¹

	Control		PMA		ATP		VEGF-165	
	-U0126	+U0126	-U0126	+U0126	-U0126	+U0126	-U0126	+U0126
Ser-279								
46 kDa	1.00	1.08±0.08	2.14±0.10*#	0.94±0.10+	0.89±0.08	0.93±0.06	1.19±0.04*	0.95±0.05+
Tyr-265								
82–78 kDa	1.00	1.14±0.06+	1.40±0.04*	1.44±0.07*	1.14±0.10	1.19±0.09	1.14±0.08*	1.09±0.07
82 kDa	1.00	1.10±0.09	1.77±0.20*	1.47±0.19*	1.14±0.11	1.14±0.14	1.20±0.12	1.04±0.11
80 kDa	1.00	1.14±0.05+	1.51±0.08*	1.56±0.08*	1.13±0.09	1.17±0.10	1.15±0.10	1.11±0.06
78 kDa	1.00	1.12±0.06	1.01±0.09	1.28±0.09*	1.15±0.12	1.21±0.11	1.15±0.10	1.12±0.07
46 kDa	1.00	1.02±0.06	1.06±0.08	0.98±0.07	0.96±0.12	1.00±0.10	1.04±0.10	1.05±0.07
Ser-368								
46 kDa	1.00	1.11±0.06	1.56±0.11*	1.37±0.09*	1.03±0.08	1.00±0.11	1.24±0.15	1.05±0.10
42 kDa ²	1.00	1.00±0.05	3.04±0.19*	2.80±0.18*	1.45±0.09*	1.21±0.11	1.29±0.15*	1.09±0.18
Ser-262								
All bands	1.00	0.83±0.11	1.40±0.10*	1.04±0.05+	0.98±0.06	0.92±0.07	1.06±0.05	0.89±0.07
44–46 kDa	1.00	0.80±0.08+	1.08±0.04	0.90±0.07	0.92±0.07	0.95±0.06	1.00±0.04	0.96±0.06
46 kDa	1.00	0.85±0.08	1.06±0.04	0.89±0.07	0.91±0.05	0.94±0.05	0.99±0.05	1.01±0.07
45 kDa	1.00	0.78±0.08+	1.09±0.04	0.92±0.08	0.95±0.07	0.97±0.06	1.04±0.04	0.94±0.06
44 kDa	1.00	0.83±0.13	1.19±0.09*	0.94±0.12	0.94±0.13	0.95±0.12	0.97±0.04	0.96±0.11
36 kDa	1.00	0.78±0.05+	1.01±0.08	0.95±0.13	0.80±0.06*	0.85±0.04*	0.91±0.12	0.97±0.08
32 kDa	1.00	0.60±0.12+	1.38±0.17*	0.66±0.09*+	1.16±0.12	0.86±0.10	1.02±0.08	0.70±0.11*+
28 kDa	1.00	0.89±0.09	2.18±0.32*	2.06±0.32*	0.89±0.09	0.85±0.12	1.07±0.09	0.97±0.16
Total Cx43								
All bands	1.00	0.98±0.06	1.10±0.07	1.03±0.07+	1.16±0.07*	1.11±0.07	1.08±0.06	0.98±0.06
46–47 kDa	1.00	0.95±0.06	1.78±0.19*	1.20±0.08*+	1.18±0.11	1.10±0.08	1.26±0.12*	1.08±0.08
42–43 kDa	1.00	1.00±0.06	0.88±0.06*	0.99±0.07+	1.18±0.07	1.15±0.07	1.04±0.06	0.98±0.05

¹Values shown are Means ± S.E.M for 5–6 independent experiments. Following frequently used nomenclature, 42 kDa=P0, 43 kDa=P1, 46 kDa=P2; 47 kDa=P3. Because some bands were difficult to measure separately due to their proximity, they were measured together.

²This band increases with alkaline phosphatase treatment.

*P<0.05 compared with control, +P<0.05 compared with same stimulated without inhibitor. #P<0.05 compared with P-UAEC.

Supplemental Table S4. Cx43 phosphorylation in P-UAEC with PMA, ATP or VEGF-165 and without or with U0126¹

	Control		PMA		ATP		VEGF-165	
	-U0126	+U0126	-U0126	+U0126	-U0126	+U0126	-U0126	+U0126
Ser-279								
46 kDa	1.00	0.84±0.07	2.85±0.14*#	0.93±0.09+	1.03±0.10	1.00±0.09	1.24±0.10*	0.84±0.05*+
Tyr-265								
82–78 kDa	1.00	1.08±0.04	1.33±0.11*	1.41±0.13*	1.10±0.08*	1.14±0.11*	1.19±0.06	1.20±0.06*
82 kDa	1.00	1.01±0.06	1.31±0.07*	1.28±0.08*	1.12±0.07	1.15±0.11	1.15±0.12	1.11±0.15
80 kDa	1.00	1.06±0.02+	1.48±0.11*	1.49±0.07*	1.07±0.04	1.15±0.11	1.07±0.10	1.06±0.16
78 kDa	1.00	1.07±0.02+	1.09±0.08	1.21±0.05*	1.04±0.05	1.15±0.13	1.04±0.11	1.09±0.19
46 kDa	1.00	1.12±0.06	1.09±0.07	1.10±0.06	1.12±0.06	1.12±0.10	1.23±0.14	1.10±0.14
Ser-368								
46 kDa	1.00	1.12±0.05*	1.26±0.09*	1.12±0.05*+	0.95±0.07	0.92±0.09	1.01±0.14	0.86±0.15
42 kDa ²	1.00	1.21±0.06+	2.69±0.21*	2.60±0.25*	1.43±0.18*	1.29±0.13*	1.26±0.23*	1.15±0.18
Ser-262								
All bands	1.00	1.00±0.04	1.32±0.12*	1.07±0.09+	1.14±0.10	1.17±0.09	1.19±0.11	0.91±0.08
44–46 kDa	1.00	1.17±0.09	1.37±0.16*	0.87±0.13+	1.01±0.12	1.26±0.11	0.99±0.05	0.82±0.09
46 kDa	1.00	1.19±0.10	1.28±0.15	0.87±0.12	1.03±0.12	1.22±0.13	1.06±0.12	0.83±0.12
45 kDa	1.00	1.17±0.12	1.42±0.18*	0.86±0.12+	0.94±0.06	1.32±0.13*+	1.11±0.15	0.83±0.07*
44 kDa	1.00	1.18±0.09	1.36±0.10*	1.07±0.20	1.01±0.10	1.25±0.13	0.93±0.08	0.77±0.07*
36 kDa	1.00	0.96±0.05	1.17±0.05*	0.96±0.15	0.93±0.06	1.05±0.04	1.11±0.10	0.85±0.07
32 kDa	1.00	0.76±0.15	1.75±0.12*	0.89±0.12+	1.15±0.04	1.09±0.17	1.48±0.18*	1.04±0.14+
28 kDa	1.00	1.07±0.17	2.21±0.34*	2.23±0.70*	1.13±0.24	0.86±0.16	1.09±0.17	0.95±0.04
Total Cx43								
All bands	1.00	0.98±0.05	1.10±0.04*	1.06±0.03	1.21±0.06*	1.15±0.05*	1.21±0.11	0.98±0.07
46–47 kDa	1.00	0.98±0.05	1.44±0.08*	1.11±0.05*+	1.09±0.06	1.00±0.08	1.13±0.14	0.92±0.12
42–43 kDa	1.00	0.98±0.04	0.92±0.05	1.03±0.02	1.21±0.06*	1.16±0.04	1.17±0.11	0.96±0.07

¹Values shown are Means ± S.E.M for 5–6 independent experiments (for the 28 kDa band of Ser-262, n=3). Following frequently used nomenclature, 42 kDa=P0, 43 kDa=P1, 46 kDa=P2; 47 kDa=P3. Because some bands were difficult to measure separately due to their proximity, they were measured together.

²This band increases with alkaline phosphatase treatment.

* P<0.05 compared with control. + P<0.05 compared with same stimulated without inhibitor. # P<0.05 compared with NP-UAEC.